Moshe Y. Levy, MD, Baylor University Medical Center, Dallas, TX, gives an overview of the use of antibody-drug conjugates (ADC) in non-Hodgkin lymphoma (NHL). Replacing vincristine in R-CHOP, the standard of care for NHL, with the anti-CD47 polatuzumab vedotin have proven to be as effective as the original R-CHOP in clinical trials, and the anti-CD19 loncastuximab tesirine has additionally demonstrated promising efficacy in patients. The two ADCs have also reported to have a favorable toxicity profile, with fewer cases of liver toxicity and neuropathy seen. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.